• In early May 2026, Neurocrine Biosciences reported first‑quarter revenue of US$814.5 million and net income of US$197.9 million, alongside multiple clinical and real‑world updates for its endocrine and neuroscience portfolio, including CRENESSITY and a new obesity candidate NBIP‑’2118.
• Beyond the headline numbers, the first expert dosing algorithms and two‑year pediatric data for CRENESSITY suggest growing medical integration of the therapy in classic congenital adrenal hyperplasia care, while the first‑in‑human obesity study marks a step toward diversifying Neurocrine’s future treatment areas.
• We’ll now examine how the strong quarterly results and CRENESSITY’s new real‑world guidance could influence Neurocrine Biosciences’ investment narrative.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Neurocrine Biosciences Investment Narrative Recap

To own Neurocrine Biosciences, you have to believe its two core franchises, INGREZZA and CRENESSITY, can support growing earnings while the broader CNS pipeline gradually adds new products. The latest quarter’s jump to US$814.5 million in revenue and US$197.9 million in net income reinforces that story, but also sharpens focus on pricing pressure and reimbursement risk for INGREZZA as the key near term swing factor, with portfolio concentration still the biggest structural risk.

The new peer reviewed glucocorticoid reduction guidelines for CRENESSITY look particularly relevant here, because they help translate trial data into everyday practice for both pediatric and adult CAH patients. If clinicians increasingly follow these structured algorithms, CRENESSITY’s role in CAH care could become more entrenched, which matters for investors watching how quickly Neurocrine can reduce its dependence on INGREZZA while managing payer scrutiny and access hurdles across the portfolio.

Yet behind these strong headlines, investors should also be aware that rising payer scrutiny and tougher coverage decisions could...

Neurocrine Biosciences' narrative projects $4.1 billion revenue and $1.0 billion earnings by 2029. This requires 13.0% yearly revenue growth and a $521.4 million earnings increase from $478.6 million today.

Uncover how Neurocrine Biosciences' forecasts yield a $186.45 fair value, a 22% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were penciling in about US$5.8 billion in 2029 revenue and US$1.8 billion in earnings, yet CRENESSITY’s evolving reimbursement profile and reliance on exceptions-based access show how much your view on future coverage and pricing can differ from theirs, and why it makes sense to compare several competing narratives before deciding what you believe.

Explore 3 other fair value estimates on Neurocrine Biosciences - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Neurocrine Biosciences research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Neurocrine Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neurocrine Biosciences' overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.